Article Text

Download PDFPDF
Differential expression of CD150 (SLAM) on monocytes and macrophages in chronic inflammatory contexts: abundant in Crohn’s disease, but not in multiple sclerosis
  1. D Theil1,
  2. C Farina2,
  3. E Meinl3
  1. 1Department of Neurology, Ludwig-Maximilians University, D-81377 Munich, Germany
  2. 2Department of Neuroimmunology, Max-Planck-Institute of Neurobiology, D-82152 Martinsried, Germany;
  3. 3Institute for Clinical Neuroimmunology, Ludwig-Maximilians University

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Signalling lymphocytic activation molecule (SLAM, CD150), originally identified as a lymphocyte activation molecule, is now known to be expressed also on mature dendritic cells and on activated monocytes. Importantly, SLAM is distinct from other monocyte activation markers because its expression on monocytes is readily induced in vitro by bacteria derived ligands of Toll-like receptors (TLRs), and not by single stimulation with inflammatory cytokines.1

    This study analysed SLAM expression on monocytes and macrophages in two distinct chronic inflammatory pathologies. In Crohn’s disease, the chronic inflammation in the gut is thought to result from inappropriate and ongoing activation of the mucosal immune system driven by the presence of normal luminal flora. The bacterial product flagellin has been suggested to be a dominant antigen in Crohn’s disease.2 Flagellin is the ligand for TLR5 and induces SLAM on monocytes.1 In contrast to Crohn’s disease, in multiple sclerosis (MS), the chronic inflammation in the central nervous system is commonly assumed not to …

    View Full Text


    • The first two authors contributed equally to this work.